IKK classic hereby announces that it will conclude non-exclusive discount agreements according to § 130a Abs. 8 SGB V with all interested and suitable pharmaceutical companies in the period from 01.05.2023 to 30.04.2025 for various active ingredients and active ingredient combinations at the same, non-negotiable conditions. The earliest start date of the contract is 01.05.2023, provided that the signed contract and all necessary proofs, self-declarations and documents are received by IKK classic by 03.04.2023. Thereafter, the following applies: Upon receipt of the documents by the 5th of a respective month in the possible accession period, the 1st of the following month shall commence the contract. Upon receipt of the documents after the 5th of a given month in the possible accession period, the 01st of the following month after next shall commence the contract. Joining the agreement is possible at any time during the specified period, but no later than 05.03.2025. For further information, see point VI.3).

Apomorphin; ATC-Code: N04BC07

Indacaterol und Mometason; ATC-Code: R03AK14

Indacaterol, Glycopyrroniumbromid und Mometason; ATC-Code: R03AL12

lamivudine and dolutegravir; ATC code: J05AR25

Oxybutynin; transdermale Pflaster; ATC-Code: G04BD04

Prednisolone; application to the eye; ATC code: S01BA04

Raltegravir; ATC-Code: J05AJ01

Rifampicin; ATC-Code: J04AB02

Vemurafenib; ATC-Code: L01EC01

Baclofen; Infusionslösung; ATC-Code: M03BX01

Benserazid und Levodopa; Retardkapseln; ATC-Code: N04BA11

Betamethason und Gentamicin; ATC-Code: D07CC01

brimonidine; single dose pipettes; ATC code: S01EA05

Cariprazin; ATC-Code: N05AX15

Deferoxamin; ATC-Code: V03AC01

dydrogesterone and estradiol; ATC code: G03FA14 or G03FB08

Formoterol und Aclidiniumbromid; ATC-Code: R03AL05